Bo Jiao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bo Jiao has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Ruibao Ren
International Center for Aging and Cancer, Hainan Medical University, Haikou 571199, China
11 shared publications Donghe Li
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 shared publications- Zhizhou Xia
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publications - Cyril H. Benes
Massachusetts General Hospital, Harvard Medical School, Boston, USA
3 shared publications - Jianming Zhang
Institute of Translational Medicine & Zhangjiang Institute for Advanced Study, Shanghai Jiao Tong University, Shanghai, 201210, China; School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai, 200240, China
3 shared publications - Jinyan Huang
Center for Biomedical Big Data, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China
3 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Targeting ZMIZ1 induces differentiation in acute myeloid leukemia via chromatin remodeling
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by profound transcriptional dysregulation and impaired hematopoietic differentiation. While differentiation therapy has revolutionized treatment in acute promyelocytic leukemia (APL), analogous strategies in non-APL AML remain elusive. Here, we identify ZMIZ1 (Zinc finger MIZ domain-containing protein 1) as a previously unrecognized transcriptional co-regulator that enforces differentiation blockade in AML from a targeted CRISPR-Cas9 screen. ZMIZ1 expression is elevated in AML patients and correlates with adverse outcomes. Genetic ablation of ZMIZ1 in leukemic cells induces terminal differentiation, reduces leukemia cell stemness, restores anti-leukemic immune responses, and significantly prolongs survival in murine AML models. Mechanistically, ZMIZ1 forms phase-separated nuclear condensates and maintains the super-enhancer architecture of genes critical for hematopoietic identity and immune evasion. Integrated Hi-C and ChIP-seq analyses reveal that ZMIZ1 cooperates with MEF2D (Myocyte-specific enhancer factor 2D) to promote enhancer-promoter looping and transcriptional output. Finally, we report the development of small-compounds potentially targeting ZMIZ1 with high binding affinity, selective on-target activity, and potent in vivo efficacy in both the murine AML model and AML organoids. Collectively, these findings uncover ZMIZ1 as a targetable epigenetic vulnerability in AML, underscoring its potential as a promising therapeutic target for differentiation-based treatment strategies.
- 19 May 2026
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 11 (1)
Open AccessTargeting ZMIZ1 induces differentiation in acute myeloid leukemia via chromatin remodeling
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy characterized by profound transcriptional dysregulation and impaired hematopoietic differentiation. While differentiation therapy has revolutionized treatment in acute promyelocytic leukemia (APL), analogous strategies in non-APL AML remain elusive. Here, we identify ZMIZ1 (Zinc finger MIZ domain-containing protein 1) as a previously unrecognized transcriptional co-regulator that enforces differentiation blockade in AML from a targeted CRISPR-Cas9 screen. ZMIZ1 expression is elevated in AML patients and correlates with adverse outcomes. Genetic ablation of ZMIZ1 in leukemic cells induces terminal differentiation, reduces leukemia cell stemness, restores anti-leukemic immune responses, and significantly prolongs survival in murine AML models. Mechanistically, ZMIZ1 forms phase-separated nuclear condensates and maintains the super-enhancer architecture of genes critical for hematopoietic identity and immune evasion. Integrated Hi-C and ChIP-seq analyses reveal that ZMIZ1 cooperates with MEF2D (Myocyte-specific enhancer factor 2D) to promote enhancer-promoter looping and transcriptional output. Finally, we report the development of small-compounds potentially targeting ZMIZ1 with high binding affinity, selective on-target activity, and potent in vivo efficacy in both the murine AML model and AML organoids. Collectively, these findings uncover ZMIZ1 as a targetable epigenetic vulnerability in AML, underscoring its potential as a promising therapeutic target for differentiation-based treatment strategies.
- Open Access
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (42) , eadv5189
Palmitoyltransferase ZDHHC19 regulates histone-to-protamine exchange during spermiogenesis in mice
Spermiogenesis, the final phrase of spermatogenesis, involves replacing histones by protamines, a process known as histone-to-protamine exchange, which is crucial for chromatin condensation. While this exchange is essential, the precise mechanisms remain incompletely understood. In this study, we discovered that the palmitoyltransferase ZDHHC19 functions as a key regulator of mouse spermiogenesis. Loss of Zdhhc19 leads to male infertility and abnormal sperm morphology. Zdhhc19 -deficient sperm exhibit impaired histone-to-protamine exchange, leading to retention of histones and misdistribution of protamines. Similarly, the palmitoyltransferase catalytic site mutant Zdhhc19 C142S knock-in mice show reduced fertility, sperm abnormalities, and histone retention. Mechanistically, ZDHHC19 mediates histone H3 palmitoylation at cysteine-110, weakening H3-H4 interactions and increasing chromatin accessibility. Palmitoylation of H3 facilitates histone-to-protamine exchange. This study highlights the essential role of ZDHHC19’s palmitoyl-transferase activity in histone-to-protamine exchange during spermiogenesis and underscores the broader role of histone palmitoylation in chromatin remodeling.
- 17 October 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (42) , eadv5189
Open AccessPalmitoyltransferase ZDHHC19 regulates histone-to-protamine exchange during spermiogenesis in mice
Spermiogenesis, the final phrase of spermatogenesis, involves replacing histones by protamines, a process known as histone-to-protamine exchange, which is crucial for chromatin condensation. While this exchange is essential, the precise mechanisms remain incompletely understood. In this study, we discovered that the palmitoyltransferase ZDHHC19 functions as a key regulator of mouse spermiogenesis. Loss of Zdhhc19 leads to male infertility and abnormal sperm morphology. Zdhhc19 -deficient sperm exhibit impaired histone-to-protamine exchange, leading to retention of histones and misdistribution of protamines. Similarly, the palmitoyltransferase catalytic site mutant Zdhhc19 C142S knock-in mice show reduced fertility, sperm abnormalities, and histone retention. Mechanistically, ZDHHC19 mediates histone H3 palmitoylation at cysteine-110, weakening H3-H4 interactions and increasing chromatin accessibility. Palmitoylation of H3 facilitates histone-to-protamine exchange. This study highlights the essential role of ZDHHC19’s palmitoyl-transferase activity in histone-to-protamine exchange during spermiogenesis and underscores the broader role of histone palmitoylation in chromatin remodeling.
- Open Access
- 10 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1462-1475
Loss of DCAF8 impairs hematopoietic stem cell function with cellular senescence via the DOCK11-CDC42 axis
Hematopoietic stem cells (HSCs) are responsible for sustaining hematopoietic system throughout life, and their functional decline contributes to hematological disorders and organismal aging. Understanding the molecular mechanisms that govern HSC function is critical for developing interventions for treating and preventing aging-related diseases. Here, we show that DCAF8, a substrate recognition component of Cullin-RING E3 ubiquitin ligases, is highly expressed in HSCs and undergoes a progressive decline with age. Loss of DCAF8 in mice results in impaired function in HSCs, characterized by increased number yet decreased self-renewal capacity, which associates with cellular senescence and elevated DNA damage. Mechanistically, DCAF8 mediates the degradation of DOCK11, a guanine nucleotide exchange factor for CDC42. In the absence of DCAF8, DOCK11 accumulates, leading to elevated CDC42 activity and consequential loss of polarity of HSCs. Knocking out Dock11 mitigates the senescence, DNA damage, and self-renewal defects of Dcaf8-/- HSCs. This study highlights a critical role of DCAF8 in preventing HSC senescence via the DOCK11-CDC42 axis and suggests potential therapeutic targets for preventing functional decline in HSCs.
- 10 July 2025
- Published by American Society of Hematology in Blood
- Vol. 146 (12) , 1462-1475
Open AccessLoss of DCAF8 impairs hematopoietic stem cell function with cellular senescence via the DOCK11-CDC42 axis
Hematopoietic stem cells (HSCs) are responsible for sustaining hematopoietic system throughout life, and their functional decline contributes to hematological disorders and organismal aging. Understanding the molecular mechanisms that govern HSC function is critical for developing interventions for treating and preventing aging-related diseases. Here, we show that DCAF8, a substrate recognition component of Cullin-RING E3 ubiquitin ligases, is highly expressed in HSCs and undergoes a progressive decline with age. Loss of DCAF8 in mice results in impaired function in HSCs, characterized by increased number yet decreased self-renewal capacity, which associates with cellular senescence and elevated DNA damage. Mechanistically, DCAF8 mediates the degradation of DOCK11, a guanine nucleotide exchange factor for CDC42. In the absence of DCAF8, DOCK11 accumulates, leading to elevated CDC42 activity and consequential loss of polarity of HSCs. Knocking out Dock11 mitigates the senescence, DNA damage, and self-renewal defects of Dcaf8-/- HSCs. This study highlights a critical role of DCAF8 in preventing HSC senescence via the DOCK11-CDC42 axis and suggests potential therapeutic targets for preventing functional decline in HSCs.
- Open Access
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
An atlas of transcriptomic changes in human immune cells driven by 364 endogenous and gut-microbiota-derived metabolites
Metabolites, particularly those derived from gut microbiota, play crucial roles in modulating immune responses, but the impact of most metabolites on immune cells remains unexplored. To systematically investigate the effect of metabolites on immune cells, we treated peripheral blood mononuclear cells (PBMCs) with 364 endogenous and gut microbiota metabolites and analyzed their impact on the PBMC transcriptome using RNA sequencing (RNA-seq). Clustering analysis revealed three distinct metabolite groups (Cluster 0, 1, 2), each exerting unique immunomodulatory effects. Cluster 1 metabolites, enhanced inflammatory pathways (e.g., cytokine signaling, neutrophil migration) and suppressed ferroptosis, potentially prolonging immune cell activity. In contrast, Cluster 0 metabolites promoted antigen presentation and extracellular matrix repair, while Cluster 2 metabolites upregulated autophagy-related pathways (e.g., GTPase signaling, ubiquitin-protein regulation), suggesting anti-inflammatory and tissue-homeostatic functions. Immune deconvolution highlighted Cluster 1-driven monocyte-to-M0 macrophage differentiation and elevated activated dendritic/mast cells, aligning with pro-inflammatory outcomes. Metabolites in Clusters 0/2 were enriched in the TCA cycle and alanine/aspartate metabolism, whereas Cluster 1 metabolites correlated with beta-alanine and branched-chain amino acid pathways. Gut microbiota analysis identified 23 species overrepresented in Cluster 1, linking dysbiosis to inflammatory metabolite profiles. Together, this high-throughput atlas elucidates how bloodborne metabolites shape PBMC function, offering insights into metabolic-immune crosstalk and potential therapeutic targets for inflammatory and autoimmune disorders.
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Open AccessAn atlas of transcriptomic changes in human immune cells driven by 364 endogenous and gut-microbiota-derived metabolites
Metabolites, particularly those derived from gut microbiota, play crucial roles in modulating immune responses, but the impact of most metabolites on immune cells remains unexplored. To systematically investigate the effect of metabolites on immune cells, we treated peripheral blood mononuclear cells (PBMCs) with 364 endogenous and gut microbiota metabolites and analyzed their impact on the PBMC transcriptome using RNA sequencing (RNA-seq). Clustering analysis revealed three distinct metabolite groups (Cluster 0, 1, 2), each exerting unique immunomodulatory effects. Cluster 1 metabolites, enhanced inflammatory pathways (e.g., cytokine signaling, neutrophil migration) and suppressed ferroptosis, potentially prolonging immune cell activity. In contrast, Cluster 0 metabolites promoted antigen presentation and extracellular matrix repair, while Cluster 2 metabolites upregulated autophagy-related pathways (e.g., GTPase signaling, ubiquitin-protein regulation), suggesting anti-inflammatory and tissue-homeostatic functions. Immune deconvolution highlighted Cluster 1-driven monocyte-to-M0 macrophage differentiation and elevated activated dendritic/mast cells, aligning with pro-inflammatory outcomes. Metabolites in Clusters 0/2 were enriched in the TCA cycle and alanine/aspartate metabolism, whereas Cluster 1 metabolites correlated with beta-alanine and branched-chain amino acid pathways. Gut microbiota analysis identified 23 species overrepresented in Cluster 1, linking dysbiosis to inflammatory metabolite profiles. Together, this high-throughput atlas elucidates how bloodborne metabolites shape PBMC function, offering insights into metabolic-immune crosstalk and potential therapeutic targets for inflammatory and autoimmune disorders.
- Open Access
- 1 July 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (4) , 101037
Identification of TMEM217 as a novel prognostic biomarker and potential therapeutic target in acute myeloid leukemia
- 1 July 2024
- Published by KEAI Publishing in Genes & Diseases
- Vol. 11 (4) , 101037
Open AccessIdentification of TMEM217 as a novel prognostic biomarker and potential therapeutic target in acute myeloid leukemia
- Open Access
- 5 February 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-15
GOLGA7 is essential for NRAS trafficking from the Golgi to the plasma membrane but not for its palmitoylation
NRAS mutations are most frequently observed in hematological malignancies and are also common in some solid tumors such as melanoma and colon cancer. Despite its pivotal role in oncogenesis, no effective therapies targeting NRAS has been developed. Targeting NRAS localization to the plasma membrane (PM) is a promising strategy for cancer therapy, as its signaling requires PM localization. However, the process governing NRAS translocation from the Golgi apparatus to the PM after lipid modification remains elusive. This study identifies GOLGA7 as a crucial factor controlling NRAS’ PM translocation, demonstrating that its depletion blocks NRAS, but not HRAS, KRAS4A and KRAS4B, translocating to PM. GOLGA7 is known to stabilize the palmitoyltransferase ZDHHC9 for NRAS and HRAS palmitoylation, but we found that GOLGA7 depletion does not affect NRAS’ palmitoylation level. Further studies show that loss of GOLGA7 disrupts NRAS anterograde trafficking, leading to its cis-Golgi accumulation. Remarkably, depleting GOLGA7 effectively inhibits cell proliferation in multiple NRAS-mutant cancer cell lines and attenuates NRASG12D-induced oncogenic transformation in vivo. These findings elucidate a specific intracellular trafficking route for NRAS under GOLGA7 regulation, highlighting GOLGA7 as a promising therapeutic target for NRAS-driven cancers.
- 5 February 2024
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-15
Open AccessGOLGA7 is essential for NRAS trafficking from the Golgi to the plasma membrane but not for its palmitoylation
NRAS mutations are most frequently observed in hematological malignancies and are also common in some solid tumors such as melanoma and colon cancer. Despite its pivotal role in oncogenesis, no effective therapies targeting NRAS has been developed. Targeting NRAS localization to the plasma membrane (PM) is a promising strategy for cancer therapy, as its signaling requires PM localization. However, the process governing NRAS translocation from the Golgi apparatus to the PM after lipid modification remains elusive. This study identifies GOLGA7 as a crucial factor controlling NRAS’ PM translocation, demonstrating that its depletion blocks NRAS, but not HRAS, KRAS4A and KRAS4B, translocating to PM. GOLGA7 is known to stabilize the palmitoyltransferase ZDHHC9 for NRAS and HRAS palmitoylation, but we found that GOLGA7 depletion does not affect NRAS’ palmitoylation level. Further studies show that loss of GOLGA7 disrupts NRAS anterograde trafficking, leading to its cis-Golgi accumulation. Remarkably, depleting GOLGA7 effectively inhibits cell proliferation in multiple NRAS-mutant cancer cell lines and attenuates NRASG12D-induced oncogenic transformation in vivo. These findings elucidate a specific intracellular trafficking route for NRAS under GOLGA7 regulation, highlighting GOLGA7 as a promising therapeutic target for NRAS-driven cancers.
- Open Access
Targeting Esophageal Squamous Cell Carcinoma by Combining Copper Ionophore Disulfiram and JMJD3/UTX Inhibitor GSK J4
The alcohol-averse drug disulfiram has been reported to have anti-tumor effects and is well suited for drug combinations. In order to identify potential drug combinations in esophageal squamous cell carcinoma (ESCC), we screened a bioactive compound library with the disulfiram copper chelation product CuET. The Jumonji domain-containing protein 3 (JMJD3) and the ubiquitously transcribed tetratricopeptide repeat protein X-linked (UTX) inhibitor GSK J4 were identified. To further understand the molecular mechanism underlying the efficient drug combination, we applied quantitative mass spectrometry to analyze the signaling pathway perturbation after drug treatment. The data revealed that the synergistic effect of GSK J4 and CuET was due to the interaction among JMJD3 and UTX, which may play important roles in maintaining endoplasmic reticulum (ER) homeostasis in tumor cells. Interestingly, our clinical data analysis showed that high expression of JMJD3 and UTX was associated with T stage and worse prognosis of ESCC patients, further supporting the importance of the above findings. In conclusion, our findings suggest that the combination of CuET and targeting JMJD3/UTX may be a safe, effective, and available treatment for ESCC.
Open AccessTargeting Esophageal Squamous Cell Carcinoma by Combining Copper Ionophore Disulfiram and JMJD3/UTX Inhibitor GSK J4
The alcohol-averse drug disulfiram has been reported to have anti-tumor effects and is well suited for drug combinations. In order to identify potential drug combinations in esophageal squamous cell carcinoma (ESCC), we screened a bioactive compound library with the disulfiram copper chelation product CuET. The Jumonji domain-containing protein 3 (JMJD3) and the ubiquitously transcribed tetratricopeptide repeat protein X-linked (UTX) inhibitor GSK J4 were identified. To further understand the molecular mechanism underlying the efficient drug combination, we applied quantitative mass spectrometry to analyze the signaling pathway perturbation after drug treatment. The data revealed that the synergistic effect of GSK J4 and CuET was due to the interaction among JMJD3 and UTX, which may play important roles in maintaining endoplasmic reticulum (ER) homeostasis in tumor cells. Interestingly, our clinical data analysis showed that high expression of JMJD3 and UTX was associated with T stage and worse prognosis of ESCC patients, further supporting the importance of the above findings. In conclusion, our findings suggest that the combination of CuET and targeting JMJD3/UTX may be a safe, effective, and available treatment for ESCC.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S9 from N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation
Supplementary Figure S1: IC50 of PDA and ODA; Supplementary Figure S2: cell number and ATP level comparison after NADA treatment; Supplementary Figure S3: NADA inhibits Ba/F3-N cell proliferation; Supplementary Figure S4: NADA induce cell death could not be rescued by z-VAD-FMK; Supplementary Figure S5: NRAS-transformed cells are more susceptible to NADA induced cell death than KRAS4B-transformed cells; Supplementary Figure S6. Effect of NADA on NRAS signaling in Ba/F3 cells; Supplementary Figure S7: NADA interrupts NRAS plasma membrane localization in a time-dependent manner; Supplementary Figure S8: Effect of NADA on palmitoylation of NRAS and cellular proteins; Supplementary Figure S9: NRAS localization in untreated GFP-NRAS-G12D transformed HeLa cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S9 from N-Arachidonoyl Dopamine Inhibits NRAS Neoplastic Transformation by Suppressing Its Plasma Membrane Translocation
Supplementary Figure S1: IC50 of PDA and ODA; Supplementary Figure S2: cell number and ATP level comparison after NADA treatment; Supplementary Figure S3: NADA inhibits Ba/F3-N cell proliferation; Supplementary Figure S4: NADA induce cell death could not be rescued by z-VAD-FMK; Supplementary Figure S5: NRAS-transformed cells are more susceptible to NADA induced cell death than KRAS4B-transformed cells; Supplementary Figure S6. Effect of NADA on NRAS signaling in Ba/F3 cells; Supplementary Figure S7: NADA interrupts NRAS plasma membrane localization in a time-dependent manner; Supplementary Figure S8: Effect of NADA on palmitoylation of NRAS and cellular proteins; Supplementary Figure S9: NRAS localization in untreated GFP-NRAS-G12D transformed HeLa cells.